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Ankylosing Spondylitis (AS) is a common inflammatory
rheumatic disease with a predilection for the axial skele-
ton, affecting 0.2% of the population. Current diagnostic
criteria rely on a composite of clinical and radiological
changes, with a mean time to diagnosis of 5 to 10 years. In
this study we employed nano liquid-chromatography
mass spectrometry analysis to detect and quantify pro-
teins and small compounds including endogenous pep-
tides and metabolites in serum from 18 AS patients and
nine healthy individuals. We identified a total of 316 pro-
teins in serum, of which 22 showed significant up- or
down-regulation (p < 0.05) in AS patients. Receiver oper-
ating characteristic analysis of combined levels of serum
amyloid P component and inter--trypsin inhibitor heavy
chain 1 revealed high diagnostic value for Ankylosing
Spondylitis (area under the curve  0.98). We also de-
pleted individual sera of proteins to analyze endogenous
peptides and metabolic compounds. We detected more
than 7000 molecular features in patients and healthy indi-
viduals. Quantitative MS analysis revealed compound pro-
files that correlate with the clinical assessment of disease
activity. One molecular feature identified as a Vitamin D3
metabolite—(23S,25R)-25-hydroxyvitamin D3 26,23-per-
oxylactone—was down-regulated in AS. The ratio of this
vitamin D metabolite versus vitamin D binding protein
serum levels was also altered in AS as compared with
controls. These changes may contribute to pathological
skeletal changes in AS. Our study is the first example of an
integration of proteomic and metabolomic techniques to
find new biomarker candidates for the diagnosis of Anky-
losing Spondylitis. Molecular & Cellular Proteomics 11:
10.1074/mcp.M111.013904, 1–11, 2012.
Ankylosing Spondylitis (AS)1 is a common inflammatory
disease affecting more than two million people in the United
States (1–3) and is associated with significant morbidity and
mortality. AS affects the axial skeleton, frequently targeting
the sacroiliac joint in the pelvis, but can also involve peripheral
joints and is associated with both uveitis and inflammatory
bowel disease. Patients suffer symptoms of back pain and
arthritis without clear diagnosis for many years (4). The etiol-
ogy of Ankylosing Spondylitis is unknown but is thought to be
immune-mediated and has a strong genetic association with
the class I human Leukocyte antigen allotype HLA-B27 (5).
Additional genes including the endopeptidase ERAP1 and the
IL23R receptor (IL23R) have also been associated with Anky-
losing Spondylitis (3, 6–8). Structural and functional studies of
endoplasmatic reticulum aminopeptidase (ERAP1) have re-
cently demonstrated altered N-terminal peptide trimming for
the AS-associated ERAP1 variant K528R, supporting a key
role for Major histocompatibility complex I-associated antigen
processing in AS pathogenesis (9, 10). Even though these
studies have contributed significantly to the understanding of
AS, the diagnosis is still challenging and is commonly based
on a composite of clinical features and sacroiliac joint radio-
logical changes, with a mean time to diagnosis of 5 to 10
years. With effective and potentially disease-modifying treat-
ments such as tumor necrosis factor (TNF) inhibitors becom-
ing widely available (11), the diagnostic delay becomes the
critical rate-limiting factor for the mobility and quality of life of
AS patients.
Blood markers such as autoantibodies against citrullinated
proteins or Rheumatoid factor are used for the early diagnosis
of Rheumatoid Arthritis with high specificity and selectivity
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such as C-reactive protein, IgG, or IgA have not archived
sufficient diagnostic sensitivity or specificity (14, 15). Recently
an array of autoantibodies in plasma targeting skeletal and
connective tissue exhibited a specificity of 60% for AS com-
pared with healthy controls or Rheumatoid Arthritis patients
(16, 17). There is also preliminary data suggesting that gene-
expression profiling may prove diagnostically useful (18). In
addition, several proteins including the metalloprotease
MMP-3 (19), CA1 (20), talin-1, and integrin-linked kinase 1
have been reported to be aberrantly expressed in the context
of AS (21). The pathology of AS is complex, and it has been
suggested that the alteration of bone growth in AS may be
uncoupled from the inflammatory process, which can be sep-
arately monitored by a differential set of biomarkers (22). Also,
TNF inhibitors given in established disease may not reduce
the abnormal bone formation in the spine (23). The diagnostic
delay and the variability of findings in previous biomarker
studies already imply that an array of markers rather than a
single compound will be more promising for an accurate
diagnosis of AS (15, 24).
In the present discovery study, we show that the mass
profile of proteins and small compounds in the serum of
individuals can be used to differentiate between AS subjects
and healthy individuals. Since the early diagnosis of AS can
have an impact on the treatment of subjects with AS, we also
present a set of molecular features that can be used to dif-
ferentiate the AS patients according to the severity of symp-
toms, represented by the Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI). We also demonstrate a
down-regulation of the Vitamin D metabolite (23S,25R)-25-
hydroxyvitamin D3 26,23-peroxylactone in our metabolomic
approach. Although its abundance in serum was in concord-
ance with levels of Vitamin D binding protein in healthy indi-
viduals, this was not the case in AS subjects. Interestingly 25-
hydroxyl Vitamin D and its metabolites are involved in the
regulation of bone formation (25), providing a potential link to
AS-associated osteoporosis. Our integrative approach repre-
sents the first study which combines the analysis of proteins
and small compounds such as metabolites to define an array
of diagnostic serum markers for AS.
EXPERIMENTAL PROCEDURES
Patients Sample Collection—Patients with definite AS (modified
New York criteria) were recruited from the Ankylosing Spondylitis
Clinic Oxford (UK) under the appropriate ethical permission Oxford-
shire REC 06/Q1606/139. These samples were used for method
development. Patient samples reported here (Table I), were obtained
under the appropriate ethical permission Queensland (AU) HREC/05/
QPAH/221. All participants gave informed, written consent.
Blood was collected from AS patients and age-gender matched
controls (supplemental Table S1) into 8 ml Vacuette Z Serum Sep Clot
TABLE I
Clinical data of the patients and controls used in this study. Clinical data were acquired on date of sampling. CRP is [mg/L], ESR is [mm/h], ALP
is [IU/L], Ca [mmol/L], PO4 is [mmol/L] and Alb is [g/L]
Number Gender Age AS/Control TNF treatment Steroids BASDAI CRP ESR ALP Ca (Alb corr) PO4 Alb
66 M 47 AS TNF None 3.4 20 8 98 2.25 1.06 38
72 M 37 AS None None 2 21 8 68 2.29 1.05 37
73 M 35 AS None None 7.2 83 84 100 2.47 0.89 36
77 M 38 Control
78 M 43 Control
83a M 61 AS previous TNF None 7.3 19 54 97 2.33 1.51 38
92 M 41 Control
93 M 30 AS None None 6.1 11 36 79 2.29 1.54 40
95 M 38 AS None 25 mg/day 9.5 149 34 69 2.15 0.94 43
96 M 18 AS NA None 7.6 98 85 84 2.37 1.21 35
99 M 35 AS None None 5.4 30 39 99 2.3 1.32 37
103 M 25 AS None None 8.8 9.1 51 104 2.2 1.32 41
104 F 37 AS None None 6.6 20 68 77 2.3 1.05 39
107 F 26 Control None
108 M 33 Control None
110 M 31 AS None None 8.4 11 25 92 2.37 1.46 43
115 M 63 AS None None 6.3 8.8 85 40 2.38 1.45 31
116 M 64 Control
120 M 32 Control
126 M 67 AS None None 5.6 34 52 86 2.28 1.06 37
128 M 41 AS None None 8 7.6 17 101 2.27 1.09 42
130 M 45 AS None 6.1 14 22 137 2.41 1.35 42
131 M 39 AS None 8.6 7.4 28 70 2.35 1.05 35
132 M 52 Control
136 M 35 AS None 5.9 14 21 97 2.48 1.51 35
140 M 35 AS None 8.9 31 39 105 2.45 1.52 35
141 M 39 Control
a Used in metabolomic study only.
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Activator tubes (Greiner, Kremsmu¨nster, Austria), left to clot at room
temperature for 2 h then spun at 3000  g for 15 min. Serum was
aliquoted and stored at 80 °C until further use.
Metabolomic Workflow—Serum of patients and healthy individuals
was centrifuged at 16000  g for 15 min and filtered through a
0.45-m syringe filter. One hundred microliters of serum were pre-
cipitated twice, using chloroform and methanol as described (26). The
protein-free aqueous phase was ultra-filtered with a MWCO of 5000
Da and the flow through was dried and resuspended in 2% acetoni-
trile, 0.1% formic acid. Samples were randomized and subjected to a
nLC-MS/MS workflow (Agilent Chip/6250 QTOF-MS) in triplicates
using a Ultra High Capacity chip (Agilent, G4240–65010) packed with
Zorbax 80SB-C18 5 m (25 mm 500 nl enrichment and 150 mm  75
m separation). Chromatographic separation was achieved by a 10
min gradient (5–40% Acetonitrile) followed by 40–98% Acetonitrile in
3 min at a flow rate of 600 nl/min. Data was acquired in positive
ionization mode at a 1.37 spectra/s between m/z 50–1700 with a
fragmentor voltage of 100 V. Tandem MS (MS/MS) spectra were
acquired with an isolation width of 1.3 m/z at 0.91 spectra/s. For
data analysis we used Progenesis LC-MS software version
3.1.4003.30577 (http://www.nonlinear.com/). Subjects were grouped
by disease state and disease activity (BASDAI). Abundance profiles of
compounds were searched manually for significant differences ac-
cording to the grouping and ANOVA p  0.01. Isotopic and chro-
matographic profile of regulated compounds was reviewed manually
and compounds exhibiting poorly defined profiles were excluded
from further analysis. Principal component analysis (PCA) was carried
out to validate clustering of patients according to their grouping either
with the curated set of regulated compounds or with a selection of
molecular features with the highest separation power between the
groups.
Proteomics and Mass Spectrometry Workflow—One hundred mi-
croliters of centrifuged and filtered serum was depleted from IgGs
and albumin according to Fu et al. (27) with minor changes. In brief,
200 l of 0.15 M NaCl was added before the incubation with 200 l
Protein G agarose beads (Invitrogen) for 1 h at room temperature. The
supernatant was combined with 200 l of 100 mM NaCl, 10 mM Tris,
pH7.4 washing solution. The solution was brought to 4 °C before
adding 396 l of cold 95% ethanol to selectively precipitate nonal-
bumin proteins. The samples were pelleted at 16,000  g and the
pellet washed with ice-cold 42% Ethanol. Proteins were resuspended
in 6 M Urea, reduced with dithiotreitol and alkylated with iodacetamide
before proteolysis with Trypsin. Tryptic digests were desalted and
subjected to LC-MS/MS (Waters, nAcquity, 75 m 250 mm, 1.7 m
particle size) analysis using a Thermo LTQ Orbitrap Velos (30,000
Resolution, Top 20, collision-induced dissociation) workflow and a
gradient of 1–40% acetonitrile in 48 min at a flow rate of 250 nl/min.
Samples were randomized and analyzed in triplicates. Peptides
were detected and quantified with Progenesis LC-MS software (ver-
sion 3.1.4003.30577) using default settings (no deconvolution/deiso-
toping, 200 most intense MS/MS peaks). A merged peaklist gener-
ated by Progenesis LC-MS was searched against the IPI human
database (version.3.80, 86719 entries) using Mascot (http://www.
matrixscience.com/) version 2.3.01, allowing one missed cleavage
and 20ppm/0.5 Da mass deviations in MS and MS/MS. Carbamido-
methylation of cysteine was a fixed modification. Oxidation of methi-
onine and deamidation of asparagine and glutamine were used as
variable modifications. Using a significance threshold of p  0.05, a
total of 158,054 out of 251,351 spectra could be matched to the IPI
human database. 3469 decoy hits were identified, indicating a false
discovery rate of 2.21%. Protein identifications were grouped into 316
groups based on the highest scoring protein in each group (summa-
rized in supplemental Table S2). For label-free protein quantitation
Mascot results were imported into Progenesis LC-MS. Similar pro-
teins were grouped and only non-conflicting features were used for
quantitation. Raw abundances were exported and used for LIMMA
analysis in R (28).
Statistical Analysis—Statistical analysis of quantified proteins was
performed using R (version 2.12.1) (29). The Linear Models for Mi-
croarray (LIMMA) package was used to identify significant differences
in protein expression between AS and control samples (28). Raw
protein abundance values from Progenesis LC-MS were first normal-
ized using quantile normalization, and technical replicates aggregated
by taking the median normalized value for each protein in each
sample. Twenty-two proteins indicated by LIMMA to be differentially
regulated in AS patients versus controls (p value  0.05, Benjamini
Hochberg correction applied) were then used to construct a logistic
regression predictive model. Bootstrap forward-backward selection
was performed using the boot.stepAIC R package to select proteins
for inclusion in the final model. Generalized predictive performance of
the final model was estimated with the bootstrap .632 method (30)
using the ModelGood package for R. Bootstrap procedures were
chosen because of the small sample size, which prohibited the use of
held-out test data or nested cross-validation methods.
RESULTS
Identification of Multiple Serum Proteins Differentially Reg-
ulated in AS—Serum samples were obtained from 18 AS
patients and nine age-gender matched healthy controls (Table
I and supplemental Table S1). IgG- and albumin-depleted
serum samples were precipitated, digested with trypsin and
analyzed in triplicates using an Orbitrap Velos (Thermo) mass
spectrometer. Following to the workflow in Fig. 1, 316 protein
groups were identified by Mascot. Two hundred and one
proteins were identified with at least two unique peptides
and quantified using a label-free approach (supplemental
Table S3). Applying LIMMA data (31) we identified 22 proteins
which were significantly up- or down- regulated in AS patients
compared with healthy individuals (Table II). Among the up-
regulated proteins were several acute phase proteins such as
C reactive protein (CRP), complement proteins, APCS and
Serpin3A. Fig. 2A shows that CRP levels measured semi-
quantitatively by MS/MS correlated extremely closely with
those obtained by ELISA-based routine biochemical analysis
at the time of sampling (R2  0.97, p  0.001).
To determine if a diagnosis of AS could be achieved using
quantitative assays for a small number of proteins, we devel-
oped a predictive logistic regression model from the obtained
MS data. Because of the small sample size precluding the use
of held-out test data or nested cross validation, we used
bootstrap procedures to create and assess this model (see
also experimental procedures). Bootstrap forward-backward
selection resulted in a final logistic regression model compris-
ing the proteins amyloid P-component serum protein (APCS)
and inter--trypsin inhibitor 2 (ITIH2). Using normalized abun-
dances of only these two proteins for classification we
achieved highly specific and sensitive detection of AS. Using
the bootstrap .632 procedure to estimate the generalized
performance of this classifier we observed an area under the
Receiver operating characteristic (ROC) curve of 0.98 (Fig.
2B). Although individually APCS and ITIH2 do not separate AS
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and control patients as strongly as other proteins, their or-
thogonality facilitates efficient classification when combined
(Fig. 2C).
Quantitation of Small Molecular Compounds in Serum Can
Discriminate AS from Healthy Controls—To enable the detec-
tion of small water-soluble molecules in serum, we denatured
and precipitated serum proteins by chloroform/methanol pre-
cipitation (26) followed by an ultrafiltration of the aqueous
phase using a 5 kDa molecular cutoff. The filtrate was dried
and resuspended in 2% acetonitrile, 0.1% formic acid fol-
lowed by Chip MS analysis (Agilent 6520) in analytical tripli-
cates. The data were acquired in MS mode to generate as
many data points for quantitation as possible and then ana-
lyzed using Progenesis LC-MS. The software detected 7813
features that exhibit at least 3 isotopic peaks with a charge
state of [MH], [M2H]2, or [M3H]3 in the compiled
dataset. The subjects were grouped according to disease
activity as measured by the Bath Ankylosing Spondylitis Dis-
ease Activity Index (BASDAI). The small molecules exhibiting
a significant differential abundance between the subject
groups, based on ANOVA scores (p 0.01) were reviewed for
a defined isotopic and chromatographic profile. We found 215
molecular features that are significantly regulated between AS
subjects and healthy controls. The PCA of these compounds
enabled a clear separation of the individuals according into
healthy or AS (Fig. 3A). However, the assessment of 215
variables in a diagnostic test is challenging, so we repeated
the PCA using the 10 molecular features with the highest
separating power only (largest negative and positive compo-
nent loadings of PC1) (supplemental Fig. S1). Using only ten
molecular features resulted in a clear separation between
healthy individuals and AS subjects. In an effort to further
distinguish between AS subjects with different disease activ-
ity, a different set of 65 molecular features that enables a
separation of at least 2 BASDAI groups was selected (ANOVA
p  0.01). PCA of these compounds permits separation and
clustering of patients according to their BASDAI group (Fig. 3
B). Although we observed some overlap between the AS
patient groups with BASDAIs of 2–6 and 6–8, this technique
clearly separated patients with the most severe disease
(BASDAI 8–10). The same set of compounds can still be used
to distinguish between AS subjects and healthy individuals in
general. Tables of the molecular features detected can be
found in the supplemental materials (supplemental Tables
S4 and S5).
The Vitamin D Metabolite (23S,25R)-25-hydroxyvitamin D3
26,23-peroxylactone Is Down-regulated in AS—In our MS-
based screening experiment for regulated profiles of molec-
ular features we detected a singly charged ion with an m/z of
445.2957, clearly resolved from the internal lock mass of
polydimethylcyclosiloxane (PCM) at 445.120024 (Fig. 4A). Be-
sides the [MH] ion we also detected [2MH] at 889.5768
(m 7 ppm) and [3MH] at 1333.857 (m 10 ppm) (data
not shown). Nine different chemical formulae were found to
match the detected mass within a mass error of  5 ppm
using Agilent’s Masshunter software (version B.03.01). How-
ever, only the formula C27H40O5 and its di-/trimer matched
the isotopic distribution of the observed ions (Figs. 4B, 4C,
and 4D). A search against the Metlin database (32) revealed
six different compounds with the chemical formula C27H40O5
FIG. 1. Workflow for accessing proteins and small molecules in serum. The proteomic workflow comprises a biochemical depletion of
IgGs and albumin followed by tryptic digest and nLC-MS analysis with a LTQ Oribitrap Velos (Thermo) instrument in triplicate. For the
metabolomic workflow, proteins in sera of AS patients and healthy individuals were precipitated with chloroform and methanol two times. The
aqueous phase was filtered through a molecular cutoff filter (5 kDa). The flow-through was analyzed for small molecules by nLC-MS with a
QTOF 6250 (Agilent) in triplicate. In both workflows the data was analyzed with Progenesis LCMS (nonlinear Dynamics).
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(m  1.9 ppm), of which five are isomers of 1,25-Dihy-
droxyvitamin D3–26,23-lactone and one is (23S,25R)-25-hy-
droxyvitamin D3 26,23-peroxylactone. m/z 445.2957 was
hardly detectable in 14 AS patients and was found at low
intensity in the remaining three (supplemental Fig. S2). Five of
the nine healthy individuals exhibited strong signal intensities
in serum whereas the compound showed low intensity in the
serum of the other four individuals (summarized in box-plot
Fig. 5A).
MS/MS analysis of m/z 445.2957 permitted the identifica-
tion of this compound as (23S,25R)-25-hydroxyvitamin D3
26,23-peroxylactone (Fig. 5B); however, the exact configura-
tion of the compound cannot be determined by the methods
used here. The diagnostic fragment ions at m/z 271.2073
(M-side chain, m  6 ppm) and 253.1867 (271.2073 - H2O,
m  33 ppm), representing the secosteroid nucleus, allow
the distinction between this vitamin D derivative and 1,25-
Dihydrovitamin D3–26,23-lactone or its isomers, in which
these fragment ions are not observed (see also (33)). Also,
these fragment ions indicate the presence of the other four
oxygen atoms in the side chain, consistent with the molecular
structure of (23S,25R)-25-hydroxyvitamin D3 26,23-peroxy-
lactone with a precursor mass of 445.2957 Da. We also mea-
sured the concentration of Vitamin D binding protein (DBP) in
the individual sera and found no significant correlation be-
tween (23S,25R)-25-hydroxyvitamin D3 26,23-peroxylactone
and DBP, although a pattern was more apparent in controls as
compared with AS (healthy controls: p  0.078, AS patients:
p  0.679, data not shown).
DISCUSSION
In this study we report MS profiling of proteins and small
compounds from the sera of AS subjects following depletion
of IgGs and Albumin (27). Three hundred and sixteen serum
proteins were detected, with 201 identified using two or more
unique peptides. We believe this list will be extremely power-
ful in future clinical studies, since all of the proteins identified
should be quantifiable using ELISA-based methods.
We show that 22 proteins are up- or down-regulated in AS
(listed in Table II, p  0.05). Most have roles in innate immu-
nity and/or the acute phase inflammatory response. Our data
thus strongly support an innate inflammatory pathogenesis in
AS, and identify key pathways for further study. These data
are complementary to the recent genetic and gene expression
data obtained in AS (5, 18). We applied LIMMA analysis to
quantify 22 proteins that are up- or down-regulated in AS
patients (p  0.05). We observed an expected up-regulation
of C-reactive protein (CRP) in AS patients, with the mass
spectrometry-derived data closely and linearly correlated with
ELISA-based measurements of CRP, confirming the validity of
TABLE II
Proteins significantly up- or down-regulated in AS compared to controls. Individual sera were IgG depleted and albumin was biochemically
removed. Proteins were digested and analysed by mass spectrometry. We identified 22 proteins which were significantly regulated between AS
and control using LC-Progenesis software (p  0.05 for significance of regulation)
log2(AS/CTRL) p value Accession IPI	 Gene Protein
Expected level in
acute phase
2.239 0.001 IPI00022389 CRP CRP Isoform 1 of C-reactive protein up52	
0.799 0.005 IPI00022395 C9 C9 Complement component C9 up52	
0.653 0.014 IPI00006543 CFHR5 CFHR5 Complement factor H-related 5 up54	
0.465 0.016 IPI00022463 TF TF Serotransferrin down52	
0.419 0.014 IPI00019591 CFB CFB cDNAFLI55673, highly similar to Complement
factor B
up52	
0.406 0.014 IPI00022391 APCS APCS Serum amyloid P-component up40	
0.405 0.035 IPI00550991 SERPINA3 SERPINA3 cDNAFLI35730fis up52	
0.310 0.047 IPI00026314 GSN GSN Isoform 1 of Gelsolin down54	
0.371 0.014 IPI00218732 PON1 PON1 Serum paraoxonase/arylesterase 1 down55	
0.374 0.041 IPI00305461 ITIH2 ITIH2 Inter-alpha (Globulin) inhibitor H2, isoform
CRA_a
up52	
0.376 0.016 IPI00027482 SERPINA6 SERPINA6 Corticosteroid-binding globulin down56	
0.394 0.035 IPI00292530 ITIH1 ITIH1 Inter-alpha-trypsin inhibitor heavy chain H1 up52	
0.441 0.036 IPI00022229 APOB APOB Apolipoprotein B-100 -
0.483 0.015 IPI00022431 AHSG AHSG cDNA FLI55606, highly similar to Alpha-2-HS-
glycoprotein
down58	
0.524 0.035 IPI00020996 IGFALS IGFALS Insulin-like growth factor-binding protein
complex acid labile subunit
-
0.531 0.008 IPI00032179 SERPINC1 SERPINC1 Antithrombin-III down57	
0.531 0.010 IPI00296099 THBS1 THBS1 Thrombospondin-1 -
0.672 0.014 IPI00016381 RAB27A RAB27A Isoform Long of Ras-related protein Rab-27A -
0.677 0.014 IPI00795528 C21orf59 C21orf59 Protein -
0.677 0.015 IPI00022432 TTR TTR Transthyretin down52	
0.767 0.014 IPI00301689 PPFIBP2 PPFIBP2 Liprin-beta-2 -
0.821 0.001 IPI00328609 SERPINA4 SERPINA4 Kallistatin down59	
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our quantitative MS approach. Besides CRP, a set of six other
proteins were up-regulated in serum from AS subjects that,
except for the iron transporter Serotransferrin, have been
reported to increase in blood during an acute phase response.
The concentration of serotransferrin typically decreases in the
context of an inflammatory response. Interestingly however,
Low et al. (34) have reported an up-regulation of serotrans-
ferrin in juvenile idiopathic arthritis. The activation, prolifera-
tion and maturation of most immune cells is iron dependent,
so that high levels of serotransferrin could directly contribute
to the pathogenesis of AS. Among the down-regulated pro-
teins in AS we observed two components of the inter--
trypsin inhibitor complex (ITIH1 and ITIH2). Both proteins have
previously been associated with multiple disorders through
their interaction with the cell surface antigen CD44 (35). ITIH1
and ITIH2 are part of the SHAP-HA multi-protein-complex
with the mucopolysaccharide hyaluronan, a determinant of
synovial fluid viscosity and modulator of TNF signaling (36).
Interestingly SHAP-HA was found in high levels in both sera
and synovial fluid from rheumatoid arthritis but not osteoar-
thritis patients (37). The down-regulation of components of
the SHAP-HA complex here observed in Ankylosing Spondy-
litis may prove useful diagnostically and could additionally
play a role in the pathogenesis of AS. Furthermore we de-
tected a down-regulation of the negative acute phase proteins
transthyretin and antithrombin-3. Kallistatin, a TNF- antago-
nist that inhibits vascular inflammation (38), appears to be
up-regulated in plasma and inflammatory joints of Rheuma-
toid Arthritis patients (39). Thus several of the “acute phase”
proteins in Table II are regulated differently in AS compared
with other chronic inflammatory conditions. We propose that
the measurement of these proteins may enable the distinction
of Ankylosing Spondylitis from other inflammatory rheumatic
diseases.
We conducted a bootstrap ROC analysis on a generated
logistic regression model in order to determine the combina-
FIG. 2. MS-based quantitation of
CRP correlates strictly with ELISA.
MS-based quantitation of APCS and
ITIH2 has diagnostic utility for Anky-
losing Spondylitis. A, CRP concentra-
tion as measured by ELISA was plotted
against median signal intensities of CRP
derived peptides measured by MS ex-
hibiting a close correlation between MS
and ELISA readout. B, ROC analysis
shows the diagnostic utility of combined
quantitation of APCS and ITIH2. C, Sig-
nal intensities of APCS and ITIH2 exhibit
orthogonality in the detection of AS. In
patients where APCS is not up-regulated
we observe a down-regulation of ITIH2
and vice versa. 1) represents two over-
laying “no AS” data points.
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tion of proteins with the strongest diagnostic value. This
method enables ROC analysis to be performed even with
the limited sample numbers used in our study. We found the
greatest diagnostic utility in combining measurement of the
up-regulated protein APCS (Serum amyloid P-component,
also SAP) with the down-regulated inter--trypsin inhibitor
subunit ITIH2. APCS has 51% sequence homology with CRP
and has been identified as acute phase protein which is
up-regulated during inflammation in mice (40). However Bijl et
al. (41) showed that APCS does not exhibit the kinetics of a
typical acute phase protein, with decreasing levels in the early
stage of inflammation and elevated levels in sustained inflam-
mation. Others have reported that APCS is slightly elevated in
Rheumatoid Arthritis and AS patients but not systemic lupus
erythematosus (42). We propose that the combined determi-
nation of APCS and ITIH2 levels in patients can contribute to
the diagnosis of Ankylosing Spondylitis with high sensitivity
and specificity. However, we recognize the limitations inher-
ent in assessing classifier performance on small sample sizes
regardless of method. Our results nevertheless suggest a
promising classification model worthy of further investigation
in different clinical groups.
As part of an integrative approach to profile changes in
serum from AS subjects, we complemented the proteomic
profiling with a metabolomic screen. The metabolomic work-
flow was designed to be fast, cost-effective and easily repro-
ducible in a clinical and analytical laboratory. The analysis of
the metabolomic samples was conducted with reversed
phase chromatography and a quadrupole time-of-flight (Q-
Tof) mass spectrometer in positive ionization mode. The limi-
tation of this configuration is that only compounds that are
water-soluble, bind to a hydrophobic stationary phase and
FIG. 3. Principal Component Analy-
sis of selected molecular features dis-
tinguishes healthy individuals from AS
patients and correlates with disease
activity. A, LC-MS analysis revealed 215
molecular features with defined chro-
matographic and isotopic profiles exhib-
iting significant differences in abun-
dance between AS and controls (ANOVA
p  0.01). Principal Component Analysis
(PCA) with this set allows separation of
AS from healthy control subjects. Ten
molecular features selected for their
highest separation power (PC1 loadings,
as visualized in the inserted diagram),
are sufficient to separate AS from con-
trols (PCA in supplemental Fig. S1). B, A
set of 65 molecular features was used
for a PCA (ANOVA p  0.01) after clas-
sifying the AS patients into BASDAI
groups, which indicate the severity of
their symptoms (PC loadings visualized
in diagram insert). Patients with most se-
vere symptoms could be separated from
the low and medium disease activity
groups. Again the control group could
be separated from the cases with the
exception of one individual (2) with
the lowest BASDAI in the cohort and one
control individual (1) with the highest age
in the control group.
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ionize well in positive mode in electro-spray are detected.
Our results show that even with these technical limitations
we can profile a highly complex but well defined subset of
small molecular features in serum without a need for pre-
fractionation. We detected molecular features that could
separate healthy individuals from AS subjects in a principal
component analysis. A refinement of this analysis to the 10
molecular features with the largest absolute loadings of PC1
was still able to differentiate between the two groups, a trait
that may be further explored in a clinical setting. Further-
more, we found a set of 65 molecular features that exhibited
a clustering of subjects according to disease activity based
on the BASDAI. Even though we did not identify these
molecular features, our data suggests that they could be
used to diagnose Ankylosing Spondylitis, even when pa-
tients suffer from less severe symptoms. Confident identi-
fications for the differential molecular features are desirable,
but the identification of hundreds of metabolites and small
compounds is challenging.
Nevertheless we successfully identified (23S,25R)-25-hy-
droxyvitamin D3 26,23-peroxylactone as a compound down-
regulated in AS by accurate mass, isotopic pattern and char-
acteristic MS/MS fragmentation. At least 37 chemically
characterized vitamin D metabolites are known, and
25(OH)D3 26,23-peroxylactone appears to be produced
from 25(OH)D3 in the kidney and secreted into the serum (43).
25(OH)D3 26,23-peroxylactone can convert nonenzymatically
into 25(OH) D3 26,23-lactone, which appears to antagonize
differentiation of leukemia cell types (44). The hormonally
active form of Vitamin D3 (1,25-dihydroxyvitamin D3) is itself
an intermediate in the production of the lactone similar to the
peroxylactone derivative identified here (45). The biological
and physiological functions of the 25(OH)D3–26,23-peroxy-
lactone are currently not fully explored, but thought to be
FIG. 4. Detection of a molecular feature at m/z 445. 2957 and matching of the measured isotopic patterns to compound
candidates with the same mass ( 5ppm). A, A singly charged compound was detected at m/z of 445.2957, well separated from the
lock-mass of PCM (MH  445.120024 Da). The left signal represents the strongest signal in the control group whereas the right signal
represents the strongest signal in the AS group. The mass of the detected compound can be matched to nine different chemical formulae. The
elemental composition of each theoretical compound generates a specific isotopic profile because of the natural abundance of heavy isotopes
of each element. The only compound matching the detected isotopic profiles of (B) the monomer at m/z 445.2957, (C) the dimer at m/z
889.5768 and (D) the trimer at m/z 1333.857 is a molecule with the monomeric formula C27H40O5.
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intermediates of lactone biosynthesis (46). Lower levels of
25(OH)D3–26,23-peroxylactone in sera of AS subjects may
therefore indicate an altered Vitamin D3 metabolism. Under
normal conditions more than 99% of Vitamin D3 and its
metabolites are bound to DBP, saturating the protein only up
to 2% (47). As expected we observed a linear trend in healthy
individuals when we compared the ELISA readouts for DBP
with the relative abundance of (23S,25R)-25-hydroxyvitamin
D3 26,23-peroxylactone. However, in AS patients DBP did not
correlate with (23S,25R)-25-hydroxyvitamin D3 26,23-peroxy-
lactone (p  0.078 in controls, p 
 0.679 in AS patients, data
not shown). Interestingly Vitamin D3 and its metabolites have
a direct influence on bone remodelling. A lower abundance of
(23S,25R)-25-hydroxyvitamin D3 26,23-peroxylactone in AS
patients could point to generally lower Vitamin D3 abundance,
reduced production of one of its intermediates upstream of
(23S,25R)-25-hydroxyvitamin D3 26,23-peroxylactone or dif-
ferential affinity of DBP or the Vitamin D3 receptor to Vitamin
D3 in AS patients due to AS-specific polymorphisms. Besides
the immune-modulatory effects of Vitamin D3 in suppressing
activated T-cells and proliferation (48), the compound has
been associated with AS and osteoporosis in various studies
(49, 50). Lower levels of Vitamin D3 may lead to an activation of
osteoclasts, increased bone resorption and reduced trans-cel-
lular calcium transport and absorption. Furthermore, it has been
reported that high levels of pro-inflammatory cytokines such as
TNF- or Interleukin-1 can modulate bone turnover in chronic
inflammation (51). All these effects converge on a decreased
bone mineral density and unbalanced bone turnover in AS pa-
tients. Our results suggest that Vitamin D3 and its metabolites
play a significant role in the pathogenesis of AS.
The relevance of the candidate molecules APCS and
ITIH2, the vitamin D3 derivative and other distinct molecular
features in discriminating between AS and healthy control sub-
jects remains to be validated in larger independent and double-
blinded patient cohorts. Discovery based studies as described
here have their limitations as far as the number of sample
processing and analysis are concerned. Even with the simple
workflows used in this study, a moderate number of individual
samples prepared in a different fashion for both metabolite and
proteome analyses with various LC-MS workflows performed in
triplicates required significant instrumental and human re-
sources. We addressed this limitation in part by the application
of bootstrap methods to generate and predict the generalized
classification performance of our AS/control prediction models
leading to increased confidence in the utility of these models
given the small-sample size.
In summary, quantitative MS analysis of proteins and small
compounds in the serum of AS and healthy control patients
provides an integrative view that accelerates the discovery of
biomarker candidates useful for the diagnosis and disease
monitoring of AS, and additionally identifies biochemical path-
ways such as vitamin D metabolism to be of potential impor-
tance in AS pathogenesis.
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